Tests a heart MRI scan without contrast for scarring in dialysis patients
Checks a heart MRI scan for scarring in adults with kidney failure on dialysis.
Plain-language title generated from the registry record
Registry title: Validating Novel, Non-contrast Cardiac MRI Imaging in Haemodialysis Patients
Key facts
- Where
- Leicester, United KingdomSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults on haemodialysis for more than 3 months who are on a supportive care register and are expected to die within 12 months. It tests a heart MRI scar measure.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- On haemodialysis for more than 3 months, on the supportive care register, with death expected within the next 12 months
- Earlier treatment
- Must have been on haemodialysis for more than 3 months
Main reasons for not taking part
- Cannot have an MRI scan (for example pacemaker, incompatible metal implants, claustrophobia)
- Expected or possible infiltrative heart muscle disease (for example amyloidosis)
- Cannot give informed consent
- Cannot understand written and spoken English
- Does not consent to donating the heart for research after death
This trial only enrols participants on dialysis. The registry sentence this rests on: Prevalent haemodialysis patient (more than 3 months)
Read by machine on 9 November 2026.
Where in United Kingdom
- University Hospitals of Leicester NHS TrustLeicester, United KingdomTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University of Leicester
- Trial code
- NCT03586518
- Record updated
- 18 April 2025
- Original description
There are currently no good ways of measuring levels of scarring in the hearts of patients with advanced kidney disease and patients on dialysis, although recent research has shown a new cardiac MRI technique, called native T1 mapping, may provide a solution to this. To assess the accuracy of this novel technique in dialysis patients, it is essential to undertake a study which compares native T1 mapping to actual levels of scarring in the hearts of patients on dialysis.Read full original descriptionShow less
Validating the Accuracy of Novel, Non-contrast, Cardiac Magnetic resOnaNce Imaging in Defining Myocardial FIbRosis in Patients With End-stage Renal Disease on haeModialysis: the CONFIRM Study
There are currently no good ways of measuring levels of scarring in the hearts of patients with advanced kidney disease and patients on dialysis, although recent research has shown a new cardiac MRI technique, called native T1 mapping, may provide a solution to this. To assess the accuracy of this novel technique in dialysis patients, it is essential to undertake a study which compares native T1 mapping to actual levels of scarring in the hearts of patients on dialysis.
Inclusion: Prevalent haemodialysis patient (more than 3 months); Active on the supportive care register with anticipated death in the subsequent 12 months; Able to give informed consent; Consent to donation of heart for research following death; Able to understand written and verbal explanations in English.
Exclusion: Contraindication to MRI scan (e.g. pacemaker, incompatible metallic implants, claustrophobia); Patients with expected or potential infiltrative cardiomyopathy (e.g. amyloidosis); Unable to give informed consent; Unable to understand written and verbal explanations in English.